Nuvo Pharmaceuticals Inc. (MRVFF)
| Previous Close | 1.1600 |
| Open | 1.2095 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 1.2095 - 1.2095 |
| 52 Week Range | 0.5900 - 1.9300 |
| Volume | 100 |
| Avg. Volume | 2,651 |
| Market Cap | 13.774M |
| Beta (5Y Monthly) | 1.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6630 |
| Earnings Date | Nov. 15, 2021 - Nov. 19, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
Miravo Healthcare™ Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference
Nuvo Pharmaceuticals Inc. (TSX:MRV) (OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it will be featured as a presenting company at the H.C. Wainwright 23rd Annual Global Investment Conference. The conference is being held as a virtual conference on September 13-15, 2021.
- CNW Group
Miravo Healthcare™ Announces Receipt of Health Canada Notice of Compliance for the Pediatric Use of Blexten®
August 12, 2021 – Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced Health Canada has issued a Notice of Compliance (NOC) in relation to the Company's Supplement to New Drug Submission for the pediatric use of Blexten. The pediatric use includes the approval of two new dosage formats; a 2.5mg/mL oral solution and a 10mg Qui
- CNW Group
Miravo Healthcare™ Announces Second Quarter 2021 Results
Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three and six months ended June 30, 2021. For further details on the results, please refer to Miravo's Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Financial Statements for the three and six month
